Results from the global phase III IMforte trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some p...
Research has shown that patients of color prefer seeing doctors of their own race — and some studies have shown health outcomes are better for Black patients seeing Black doctors.
In a recent article, the use of tyrosine kinase inhibitors in treating EGFR-variant lung adenocarcinoma is explored, drawing comparisons to their use in chronic myeloid leukemia, highlighting similarities and differences.
Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.
A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.